F-031
氟康唑标准液 溶液
2.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C13H12F2N6O
化学文摘社编号:
分子量:
306.27
UNSPSC Code:
41116107
PubChem Substance ID:
EC Number:
200-659-6
NACRES:
NA.24
MDL number:
SMILES string
Fc1c(ccc(c1)F)C(O)(C[n]3ncnc3)C[n]2ncnc2
InChI
1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2
InChI key
RFHAOTPXVQNOHP-UHFFFAOYSA-N
grade
certified reference material
form
liquid
feature
(Snap-N-Spike®)
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
2.0 mg/mL in methanol
technique(s)
gas chromatography (GC): suitable, liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
storage temp.
−20°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
General description
Fluconazole, sold under trade names such as Trican, Monicure, Diflucan®, and Afungil, is an antifungal drug used in the treatment and prevention of superficial and systemic fungal infections. This Certified Spiking Solution® is suitable as starting material for calibrators, controls, or linearity standards for therapeutic drug monitoring or clinical and diagnostic testing of fluconazole in patient blood, serum, or plasma samples by HPLC or LC-MS/MS.
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Diflucan is a registered trademark of Pfizer, Inc.
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
target_organs
Eyes,Central nervous system
存储类别
3 - Flammable liquids
wgk
WGK 2
flash_point_f
49.5 °F - closed cup
flash_point_c
9.7 °C - closed cup
法规信息
危险化学品
此项目有
K Turner et al.
Current medicinal chemistry, 19(27), 4617-4620 (2012-08-11)
Invasive candidiasis (IC) in the premature infant population is a common infection that results in substantial morbidity and mortality. For these patients, fluconazole is among the first line therapies to treat and prevent IC, and yet few prospective studies investigating
Maria I Rosa et al.
European journal of obstetrics, gynecology, and reproductive biology, 167(2), 132-136 (2013-01-03)
To investigate the efficacy, compared to placebo, of fluconazole 150 mg weekly, given for six months as prophylaxis against recurrent vulvovaginal candidiasis (RVVC). A quantitative systematic review was performed, and randomized controlled trials were included. We conducted searches at Medline
Jenny Wan Sai Cheong et al.
Medical mycology, 51(3), 261-269 (2012-09-20)
With the widespread use of long-term fluconazole prophylaxis and suppressive treatment, the potential development of fluconazole resistance poses a threat to the management of cryptococcal disease. Interpretive breakpoints for the in vitro antifungal susceptibility testing of C. neoformans have not
M C Ethier et al.
British journal of cancer, 106(10), 1626-1637 (2012-05-10)
Objectives were to compare systemic mould-active vs fluconazole prophylaxis in cancer patients receiving chemotherapy or haematopoietic stem cell transplantation (HSCT). We searched OVID MEDLINE and the Cochrane Central Register of Controlled Trials (1948-August 2011) and EMBASE (1980-August 2011). Randomised controlled
Epidemiology and prevention of neonatal candidiasis: fluconazole for all neonates?
David A Kaufman
Advances in experimental medicine and biology, 659, 99-119 (2010-03-06)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持